DSGN
Price:
$6.14
Market Cap:
$347.65M
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment o...[Read more]
Industry
Biotechnology
IPO Date
2021-03-29
Stock Exchange
NASDAQ
Ticker
DSGN
According to Design Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 319.85M. This represents a change of 70.85% compared to the average of 187.21M of the last 4 quarters.
The mean historical Enterprise Value of Design Therapeutics, Inc. over the last ten years is 724.41M. The current 319.85M Enterprise Value has changed 4.32% with respect to the historical average. Over the past ten years (40 quarters), DSGN's Enterprise Value was at its highest in in the March 2020 quarter at 1.13B. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.
Average
724.41M
Median
688.64M
Minimum
130.21M
Maximum
1.13B
Discovering the peaks and valleys of Design Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Enterprise Value = 1.13B
Minimum Annual Increase = -76.27%
Minimum Annual Enterprise Value = 130.21M
Year | Enterprise Value | Change |
---|---|---|
2023 | 130.21M | -76.27% |
2022 | 548.75M | -20.31% |
2021 | 688.64M | -38.83% |
2020 | 1.13B | -0.27% |
The current Enterprise Value of Design Therapeutics, Inc. (DSGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
455.87M
5-year avg
724.41M
10-year avg
724.41M
Design Therapeutics, Inc.’s Enterprise Value is less than Monte Rosa Therapeutics, Inc. (396.71M), greater than Werewolf Therapeutics, Inc. (-9845928.00), greater than Ikena Oncology, Inc. (43.31M), less than Stoke Therapeutics, Inc. (504.84M), greater than Achilles Therapeutics plc (-41742960.00), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Magenta Therapeutics, Inc. (-114170976.00), greater than Graphite Bio, Inc. (-15007658.00), greater than ALX Oncology Holdings Inc. (68.63M), greater than Aadi Bioscience, Inc. (29.81M), greater than ADC Therapeutics SA (248.68M), greater than AlloVir, Inc. (-63695180.00), less than Gracell Biotechnologies Inc. (5.64B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Erasca, Inc. (727.63M), less than Cullinan Oncology, Inc. (610.74M), less than Immunocore Holdings plc (1.46B), greater than C4 Therapeutics, Inc. (312.39M),
Company | Enterprise Value | Market cap |
---|---|---|
396.71M | $478.59M | |
-9845928.00 | $76.20M | |
43.31M | $80.11M | |
504.84M | $652.55M | |
-41742960.00 | $40.69M | |
-6333315.00 | $8.20M | |
-114170976.00 | $42.44M | |
-15007658.00 | $185.19M | |
68.63M | $74.90M | |
29.81M | $59.40M | |
248.68M | $191.45M | |
-63695180.00 | $53.16M | |
5.64B | $989.87M | |
138.26M | $181.50M | |
727.63M | $743.57M | |
610.74M | $710.38M | |
1.46B | $1.52B | |
312.39M | $304.94M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Design Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Design Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Design Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Design Therapeutics, Inc. (DSGN)?
What is the 3-year average Enterprise Value for Design Therapeutics, Inc. (DSGN)?
What is the 5-year average Enterprise Value for Design Therapeutics, Inc. (DSGN)?
How does the current Enterprise Value for Design Therapeutics, Inc. (DSGN) compare to its historical average?